PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.83%
Negative revenue growth while 3141.T stands at 2.43%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.74%
Negative gross profit growth while 3141.T is at 7.88%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.58%
Negative EBIT growth while 3141.T is at 56.08%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-25.27%
Negative operating income growth while 3141.T is at 63.95%. Joel Greenblatt would press for urgent turnaround measures.
-11.81%
Negative net income growth while 3141.T stands at 64.31%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-11.81%
Negative EPS growth while 3141.T is at 64.15%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-11.81%
Negative diluted EPS growth while 3141.T is at 64.39%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3141.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.88%
10Y revenue/share CAGR at 50-75% of 3141.T's 64.89%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-7.45%
Negative 5Y CAGR while 3141.T stands at 54.51%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
38.84%
3Y revenue/share CAGR above 1.5x 3141.T's 25.29%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.01%
Below 50% of 3141.T's 508.97%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
16.46%
Below 50% of 3141.T's 272.31%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
59.57%
3Y net income/share CAGR 50-75% of 3141.T's 85.14%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
131.98%
10Y equity/share CAGR at 75-90% of 3141.T's 152.05%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
27.65%
Below 50% of 3141.T's 116.50%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.35%
3Y equity/share CAGR similar to 3141.T's 62.61%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Negative 5Y dividend/share CAGR while 3141.T stands at 150.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-30.00%
Negative near-term dividend growth while 3141.T invests at 66.67%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-12.20%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
6.37%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
1.87%
Asset growth above 1.5x 3141.T's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.11%
1.25-1.5x 3141.T's 4.40%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-6.73%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
2.77%
SG&A growth well above 3141.T's 1.49%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.